Form 4: SOPHIA GENETICS SA: Executive Chairman Sells Shares

SOPHIA GENETICS SA Executive Chairman Jurgi Camblong sold 22,486 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

Summary

• Jurgi Camblong, Executive Chairman of SOPHiA GENETICS SA, sold 22,486 ordinary shares on July 6, 2026.
• The sale was conducted to satisfy tax withholding obligations stemming from the vesting of restricted stock units on July 2 and July 3, 2026.
• These transactions were executed as part of a pre-established Rule 10b5-1(c) trading plan, indicating they were not discretionary.
• The shares were sold at a weighted average price of $5.255, with individual sales ranging from $4.97 to $5.43.
• Following these transactions, Camblong beneficially owns 3,558,807 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a sale of shares by a key executive can sometimes be perceived negatively, the clear explanation that it was for tax withholding and executed under a Rule 10b5-1 plan mitigates significant concern.

Positives

• The sale was conducted under a Rule 10b5-1(c) trading plan, which is designed to provide an affirmative defense against allegations of insider trading.
• The sale was for the purpose of covering tax withholding obligations, a common and expected event for executives receiving equity awards.
• The reporting person retains a significant beneficial ownership of 3,558,807 ordinary shares.

Negatives

• A notable number of shares (22,486) were sold by a key executive.
• The sale reduces the direct shareholding of the Executive Chairman.

Risks

• While conducted under a 10b5-1 plan, any significant executive selling can be perceived negatively by the market.
• The weighted average sale price of $5.255 might be lower than the price at which the RSUs vested, though this is not explicitly stated as a negative.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports on a completed transaction.

Management Comments

• Sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by SOPHiA GENETICS SA's Executive Chairman is a common practice to manage equity sales transparently and avoid potential insider trading concerns, especially in the biotechnology and healthcare technology sectors where equity-based compensation is prevalent.

Stakeholder Impact

• Shareholders: The sale reduces the direct shareholding of the Executive Chairman, but the explanation of it being for tax purposes under a 10b5-1 plan should limit negative sentiment.
• Employees: The transaction relates to executive compensation and vesting of RSUs, which is a standard component of employee incentive structures.
• Management: The transaction confirms the use of established governance practices for executive equity management.

Next Steps

• The reporting person will continue to hold 3,558,807 ordinary shares.
• The company may receive written requests for detailed information on the share sales.

Key Dates

Keywords

SOPHiA GENETICS SA, Form 4, Insider Trading, Rule 10b5-1, Executive Compensation, Stock Sale, Restricted Stock Units, Beneficial Ownership, Jurgi Camblong